Jose Fernando Moura, PhD
@FernandoOnco
Followers
2K
Following
14K
Media
890
Statuses
7K
Apaixonado por oncologia. Compartilho novidades na área Siga para insights e conversas! Câncer de mama, câncer de pulmão, pesquisa clínica, AI, inovação
Recife, Brasil
Joined January 2011
RT @DrMirallas: 🙌🏽 I can't agree more @GIMedOnc . 🤯 What an amazing work @NatureMedicine . 💥 Phase I AMPLIFY-201: ELI-002 (KRAS vaccine).🧪….
0
6
0
RT @realbowtiedoc: #GIonc in @JAMAOnc . #ACCORD trial: .Adjuvant camrelizumab + chemoradiation vs observation in resected EHC/GBC (n=93) #h….
0
17
0
🌍 Oncology never stops evolving. Every week, @OncoAlert RoundUp brings you the most relevant papers across all fields of oncology—curated, concise, and impactful. 🔗 Join the , expand your network, and stay at the cutting edge of cancer research with.
The OncoAlert WEEKLY RoundUp 🚨 .Covering the TOP of the week August 8-14, 2025. 👉REGISTER at OR . Discussing:.✅Extending the duration of ET for early #BreastCancer . ✅Nemvaleukin alfa monoTX in advanced #Melanoma
1
1
9
We need know more about awareness in others tumors . If HIC have low awareness I imagine that LMIc would have more problems in this situations . @JAMAOnc @OncoAlert.
jamanetwork.com
This cross-sectional study aims to quantify awareness of human papillomavirus (HPV), the HPV vaccine, and its association with cancer across 50 states and Washington, DC.
0
3
12
RT @pashtoonkasi: 🆕🗞️Hot off the press! @NatureMedicine. #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽. More to come w….
0
100
0
RT @OncoAlert: Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blocka….
0
8
0
RT @realbowtiedoc: New #survonc stats from @CACancerJournal. >1.4M in the 🇺🇸 live with #crcsm.⬆️incidence in #AYA .Survival ⬆️to 64% .Dispa….
0
11
0
RT @OncoAlert: Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastu….
0
8
0
RT @Lucarecco: Is it possible to avoid adjuvant CT in older patients (≥70y) with HR+ BC at higher risk of recurrence?.Published in @TheLanc….
0
10
0
RT @OncoAlert: Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative….
0
15
0
RT @nataliagandur: 🌟🔝 LATAM 💰💡 What if we could save $244 million/year while improving cancer care access in LATAM?.🔹 Economic Benefits of….
0
11
0
Thank you for your presence and presentation here at our institution. We hope to see you soon and stay focused for longer! @BRicciutiMD @OncoAlert #OncoAlertAF Real Hospital Português
2
3
12
RT @OncoAlert: The OncoAlert WEEKLY RoundUp 🚨 .Covering the TOP of the week July 25-31, 2025 . 👉REGISTER at OR….
0
16
0
RT @Lucarecco: Do gBRCA PVs impact CDK4/6i efficacy in HR+/HER2– MBC?. This M-A in @TheBreastOnline included 16,884 pts (618 BRCA) and show….
0
38
0
Biagio, it will be an honor to welcome you to our institution. I'll be on vacation, but you'll be warmly welcomed! @BRicciutiMD @OncoAlert #LCSM
1
3
14
Aos #oncologistas brasileiros 🇧🇷 , recomendo acompanhar o @OncoAlert para atualizações sobre os principais eventos e artigos em oncologia, com grandes nomes nas diversas áreas da especialidade @GBOT_Alerta @GBECAMConnect @LACOG_group @SBOC_Oncologia.
The OncoAlert WEEKLY RoundUp 🚨.Covering the TOP of the week July 11-17, 2025 . 👉REGISTER at OR Discussing:.✅TALAPRO2 in #ProstateCancer.✅Geriatric Assessment 👴.✅Molecular Landscape of Non Clear Cell Renal Carcinoma
0
1
4
RT @BRicciutiMD: Check out the latest 🚨@OncoAlert 🚨.Round Up covering the TOP of the week July 11-17, 2025 by @weoncologists!. & don’t fo….
0
4
0
RT @realbowtiedoc: New editorial in @MASCC_JSCC . @NaomiTakemura discusses as #SurvOnc ⬆️ many face complex challenges . Adapting #Treatabl….
0
9
0
RT @realbowtiedoc: Over the next 2 weeks hope to do some quick #video summaries of our #Top10Tips paper for #hpm on #survonc. Hope you enjo….
0
26
0